AZGP1 and cancer: In both TCGA-PRAD and MSKCC-PRAD, we divided samples at the median AZGP1 expression level into high and low expression cancers and found that low AZGP1 expression was significantly associated with poor disease-free survival outcomes (Fig. 7A, B), Additionally, low AZGP1 expression was associated with higher Gleason scores in both datasets (Fig. 7C, D).